News from the FDA: New ovarian cancer treatment and imaging drug

https://www.facingourrisk.org/XRAY/news-from-FDA-ovarian-cancer-May2024

Full article: https://www.fda.gov/drugs/development-approval-process-drugs

The FDA recently approved a new treatment for some people with ovarian cancer. The FDA also approved a new imaging drug that can help surgeons find and remove ovarian cancer. (Posted 5/30/24)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Am I a candidate for treatment with ELAHARE?
What are the most common side effects I can expect with ELAHARE?
Is Cytalux regularly used during surgery to remove ovarian cancer at this institution?
Am I a candidate for Cytalux during my ovarian cancer surgery?

Open Clinical Trials

The following are studies looking at PARP inhibitors and similar agents for treating people with ovarian cancer.

NCT03579316: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. This studies how well adavosertib with or without olaparib work in patients with ovarian cancer that has come back (recurrent).

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.